Abstract:Purpose: Ceftazidime/avibactam (CAZ/AVI) monotherapy and polymyxin B-based combination therapy are currently two treatment options for patients with carbapenem-resistant Pseudomonas aeruginosa (CRPA) infection; however, few studies have contrasted the relative efficacy of the two antibiotic regimens. The purpose of this study was to compare the effectiveness of CAZ/AVI and polymyxin B against CRPA infection and analyze the independent predictors of 30-day mortality or survival. Patients and Methods: This single-center retrospective observational study included patients with CRPA infection treated with CAZ/AVI or polymyxin B between January 2018 and December 2020. The primary outcomes were the 14-day and 30-day mortality. The secondary outcomes were in-hospital mortality and bacterial clearance. Baseline characteristics and outcomes were compared between the two groups, and COX regression analysis was used to identify predictors of 30-day mortality. Results: A total of 136 patients with CRPA infection were enrolled, including 51 patients in the CAZ/AVI group and 85 patients in the polymyxin B group. The 14-day mortality (5.9% vs 27.1%, p=0.002), 30-day mortality (13.7% vs 47.1%, p<0.001) and in-hospital mortality (29.4% vs 60.0%, p=0.001) in the CAZ/AVI group were significantly lower than the polymyxin B group. The bacterial clearance rate (45.1% vs 12.9%, p<0.001) in the CAZ/AVI group were higher than in the polymyxin B group. After adjustment by propensity score matching, the CAV/AVI group still had lower 30-day mortality (14.3% vs 42.9%, p=0.018) and higher bacterial clearance rate (42.9% vs 14.3%, p=0.018) than the polymyxin B group. The multivariate COX analysis showed that the age was identified as independent predictor of 30-day mortality while CAZ/AVI therapy and central venous catheterization emerged as independent predictors of 30-day survival. Conclusion: CAZ/AVI therapy was superior to polymyxin B therapy for patients with CRPA infection, and provided significant survival benefits, but further larger studies were needed to substantiate our findings.

A multicenter, open-label, randomized controlled clinical trial to compare biapenem with meropenem in the treatment of bacterial pneumonia and urinary tract infections

Analysis of efficacy and safety of panipenem/betamipron in treatment of 30 patients with severe bacterial infection

A randomized, controlled clinical trial of meropenem and imipenem/cilastatin in the treatment of acute bacterial infections]

Multicenter Randomized Controlled Clinical Trial on Teicoplanin Versus Vancomycin

Ceftazidime/Avibactam versus Polymyxin B in the Challenge of Carbapenem-Resistant <i>Pseudomonas</i> aeruginosa Infection

A meta-analysis of the efficacy and safety of meropenem and imipenem in the treatment of moderate or severe pulmonary infections

Comparison of Antibacterial Activity in Vitro of Two Pharmaceutical Products of Meropenem Injection

A Multicenter Clinical Trial on the Efficacy and Safety of Piperacillin/tazobactam for the Treatment of Patients with Hospital Acquired Pneumonia: Treatment of Hospital Acquired Pneumonia Forum in Huadong Area.

Tolerability and Pharmacokinetics of Biapenem Following Single and Multiple Intravenous Administrations in Healthy Chinese Subjects: an Open-Label, Randomized, Single-Center Study.

Pharmacodynamics of biapenem in severe pulmonary infection patients with continuous renal replacement therapy

Multicenter Clinical Study on Piperacillin/Sulbactam for Treatment of Respiratory and Urinary Tract Infection

Evaluation of Biapenem Regimens in Treatment of Gram-Negative Bacterial Infections with Monte Carlo Simulation

Population Pharmacokinetics, Dosing Optimization and Clinical Outcomes of Biapenem in Patients with Sepsis

Analysis of factors related to clinical efficacy of biapenem in bacteria infected patients

[The Efficacy and Safety of Different Antimicrobial Regimens in Carbapenem-Resistant Klebsiella Pneumoniae Bloodstream Infections].

Efficiency of Polymyxin B Treatment Against Nosocomial Infection: a Systematic Review and Meta-Analysis

Efficacy and safety of piperacillin–tazobactam compared with meropenem in treating complicated urinary tract infections including acute pyelonephritis due to extended-spectrum β-lactamase-producing Enterobacteriaceae

Randomized control study of the use of faropenem for treating patients with pulmonary tuberculosis

A multicenter,randomized,and double-blind controlled clinical trial of cefepime in treatment of acute bacterial infections

A Randomized Controlled Clinical Trial of Piperacillin/Tazobactam Versus Imipenem/Cilastatin in the Treatment of Bacterial Infections

Comparison of effect of different infusion of meropenem for patients with sepsis in ICU